Randomized, Placebo-controlled, Dose-escalation, Double-blind Study of Dasiglucagon Effects on QTc in Healthy Volunteers

First published in Current Therapeutic Research in 2022.
Current Therapeutic Research, Volume 96, 2022, Article 100668 doi.org/10.1016/j.curtheres.2022.100668

Authors: Ramin Tehranchi MD, PhD, MBA, Anita E.Melgaard MSc, Friedeborg Seitz MD, Anders Valeur PhD, Stine Just Maarbjerg PhDS

Download full article as Pdf file:

Pdf File

REACHING OUT IS EASY AND FAST – LET’S TALK

Prof. Dr. Thomas Forst

Chairman of the Executive Board
located at CRS Mannheim

LET’S TALK SCIENCE

+49 621 150 45 – 0

Dr. Marc Hetzel

VP & Head of Business Development
located at CRS Management

LET’S TALK BUSINESS

+49 621 150 45 – 0

Randomized, Placebo-controlled, Dose-escalation, Double-blind Study of Dasiglucagon Effects on QTc in Healthy Volunteers

Read more

REACHING OUT IS EASY AND FAST – LET’S TALK

You May Also Like

Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects.

Midazolam microdosing applied in early clinical development for drug-drug interaction assessment.

The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive – A randomized controlled trial.